Free Trial

Codexis Q1 2023 Earnings Report

Codexis logo
$2.29 -0.20 (-8.03%)
As of 04/3/2025 04:00 PM Eastern

Codexis EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.13

Codexis Revenue Results

Actual Revenue
$12.98 million
Expected Revenue
$14.09 million
Beat/Miss
Missed by -$1.11 million
YoY Revenue Growth
-63.30%

Codexis Announcement Details

Quarter
Q1 2023
Time
After Market Closes
Remove Ads

Codexis Earnings Headlines

Codexis appoints new independent board member
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Codexis appoints new independent board member
See More Codexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email.

About Codexis

Codexis (NASDAQ:CDXS) discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

View Codexis Profile

More Earnings Resources from MarketBeat